These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 33969715)

  • 1. Reducing metabolic syndrome in Australian patients: Metabolic Management During Antipsychotic Prescribing (MMAP) programme.
    Castle DJ; Hopwood M; Rege S; George DB
    Australas Psychiatry; 2022 Feb; 30(1):84-89. PubMed ID: 33969715
    [No Abstract]   [Full Text] [Related]  

  • 2. Psychiatrists' attitudes toward metabolic adverse events in patients with schizophrenia.
    Sugawara N; Yasui-Furukori N; Yamazaki M; Shimoda K; Mori T; Sugai T; Suzuki Y; Someya T
    PLoS One; 2014; 9(1):e86826. PubMed ID: 24466260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for the metabolic syndrome in Australia: a national survey of psychiatrists' attitudes and reported practice in patients prescribed antipsychotic drugs.
    Laugharne J; Waterreus AJ; Castle DJ; Dragovic M
    Australas Psychiatry; 2016 Feb; 24(1):62-6. PubMed ID: 26635377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antipsychotic prescription assessment in general practice: metabolic effects].
    Gignoux-Froment F; de Montleau F; Saravane D; Verret C
    Encephale; 2012 Dec; 38(6):453-9. PubMed ID: 23200610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists.
    Newcomer JW; Nasrallah HA; Loebel AD
    J Clin Psychopharmacol; 2004 Oct; 24(5 Suppl 1):S1-6. PubMed ID: 15356414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for the metabolic side effects of antipsychotic medication: findings of a 6-year quality improvement programme in the UK.
    Barnes TR; Bhatti SF; Adroer R; Paton C
    BMJ Open; 2015 Oct; 5(10):e007633. PubMed ID: 26428329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic prescribing: do conflict of interest policies make a difference?
    Anderson TS; Huskamp HA; Epstein AJ; Barry CL; Men A; Berndt ER; Horvitz-Lennon M; Normand SL; Donohue JM
    Med Care; 2015 Apr; 53(4):338-45. PubMed ID: 25769055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient, Physician and Organizational Influences on Variation in Antipsychotic Prescribing Behavior.
    Tang Y; Chang CC; Lave JR; Gellad WF; Huskamp HA; Donohue JM
    J Ment Health Policy Econ; 2016 Mar; 19(1):45-59. PubMed ID: 27084793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Audit of antipsychotic prescribing in a private psychiatric hospital.
    Botvinik L; Ng C; Schweitzer I
    Australas Psychiatry; 2004 Sep; 12(3):227-33. PubMed ID: 15715780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Questionable antipsychotic prescribing remains common, despite serious risks.
    Kuehn BM
    JAMA; 2010 Apr; 303(16):1582-4. PubMed ID: 20424239
    [No Abstract]   [Full Text] [Related]  

  • 11. Antipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points.
    McMillan SS; Jacobs S; Wilson L; Theodoros T; Robinson G; Anderson C; Mihala G; Wheeler AJ
    BMC Psychiatry; 2017 Apr; 17(1):139. PubMed ID: 28407747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychiatrists' attitudes about and informed consent practices for antipsychotics and tardive dyskinesia.
    Schachter DC; Kleinman I
    Psychiatr Serv; 2004 Jun; 55(6):714-7. PubMed ID: 15175474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care.
    Nasrallah HA; Newcomer JW
    J Clin Psychopharmacol; 2004 Oct; 24(5 Suppl 1):S7-14. PubMed ID: 15356415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RedUSe: reducing antipsychotic and benzodiazepine prescribing in residential aged care facilities.
    Westbury JL; Gee P; Ling T; Brown DT; Franks KH; Bindoff I; Bindoff A; Peterson GM
    Med J Aust; 2018 May; 208(9):398-403. PubMed ID: 29747564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Awareness of metabolic concerns in patients with bipolar disorder: a survey of European psychiatrists.
    Bauer M; Lecrubier Y; Suppes T
    Eur Psychiatry; 2008 Apr; 23(3):169-77. PubMed ID: 18160267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic syndrome associated with schizophrenia and atypical antipsychotics.
    Hasnain M; Fredrickson SK; Vieweg WV; Pandurangi AK
    Curr Diab Rep; 2010 Jun; 10(3):209-16. PubMed ID: 20425584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of hospitalization for stroke associated with antipsychotic use in the elderly: a self-controlled case series.
    Pratt NL; Roughead EE; Ramsay E; Salter A; Ryan P
    Drugs Aging; 2010 Nov; 27(11):885-93. PubMed ID: 20964462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attitudes of psychiatrists toward antipsychotic depot medication.
    Heres S; Hamann J; Kissling W; Leucht S
    J Clin Psychiatry; 2006 Dec; 67(12):1948-53. PubMed ID: 17194274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Who is responsible for metabolic screening for mental health clients taking antipsychotic medications?
    Ward T; Wynaden D; Heslop K
    Int J Ment Health Nurs; 2018 Feb; 27(1):196-203. PubMed ID: 28093900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How quickly do physicians adopt new drugs? The case of second-generation antipsychotics.
    Huskamp HA; O'Malley AJ; Horvitz-Lennon M; Taub AL; Berndt ER; Donohue JM
    Psychiatr Serv; 2013 Apr; 64(4):324-30. PubMed ID: 23280376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.